Fu Wei

Fu Wei, listed as chief executive, has filed trades across 2 companies (mainly through HKEX), most often in Everest Medicines Ltd. and Ascletis Pharma Inc. - B. We count 22 filings; the first trade dates from 1 August 2018 and the latest from 17 June 2026.

Market trades split into 11 purchases (€297.1M) and 6 sales (€425.2M). The totals exclude 2 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2026, the count stands at 9 purchases and no sales.

The median purchase comes to €1.7M. Relative to company size, the median is 0.14% of market cap (9 purchases with a known value). 10 out of 11 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Ninety days after publication, 9 purchases show a median change of +3.1%, with the price up in 67% of them. Past outcomes like these are no guarantee of what comes next.

The latest filing, published on 23 June 2026, reports an open-market purchase of €1.5M in Everest Medicines Ltd. Typically, a trade is published a median of 5 days after it takes place. This delay matters because a trade only becomes useful information once it is public. This summary is built from HKEX disclosures alone and does not predict where the share price will go.